8-K current report · filed Aug 12, 2026

Annexon, Inc. (ANNX) 8-K Current Report: August 12, 2026

Item 8.01Item EX-99.1Item EX-99.2Item 2.02ANNX overview

Short answer

Annexon, Inc. (ANNX) filed an 8-K current report with the SEC on August 12, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 2.02 (Results of Operations and Financial Condition). Annexon announced financial results for Q2 2026, ended June 30, 2026.

Annexon, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Annexon announced financial results for Q2 2026, ended June 30, 2026
  • Press release includes business updates and anticipated milestones relevant to clinical and corporate catalysts
  • Exhibit 99.1 contains the detailed financial results and management updates

Item 8.01 · Other Events

  • Annexon expanded vonaprument’s Phase 3 geographic atrophy program with a Month 24 dual primary endpoint
  • Month 24 endpoint complements the existing Month 15 primary endpoint
  • Open-label extension study launch extends patient follow-up and may provide additional long-term efficacy and safety data
  • Details and management commentary are provided in Exhibit 99.2

Item EX-99.1 · Exhibit EX-99.1

  • Q2 net loss $55.3M, or $0.28 per share, versus $49.2M and $0.34 in Q2 2025
  • Cash, equivalents and short-term investments $209.2M at June 30, with runway expected into 2028
  • Oxford Finance credit facility up to $200M, including $50M initially drawn, strengthening near-term funding
  • Tanruprubart BLA submission expected in Q4 2026 following positive FORWARD GBS outcomes
  • Vonaprument Month 15 ARCHER II endpoint remains on track for Q4 2026, with Month 24 completion expected Q3 2027

Item EX-99.2 · Exhibit EX-99.2

  • ARCHER II adds Month 24 as a dual primary endpoint, creating a second opportunity to demonstrate vision-loss protection
  • Month 15 primary-endpoint assessment remains on schedule for Q4 2026, the next major valuation catalyst
  • Month 24 analysis expected Q3 2027, extending the pivotal trial timeline and delaying full efficacy readout
  • Trial execution remains strong: 659 patients, discontinuation below 10%, compliance above 95%
  • Open-label extension offers monthly vonaprument after Month 24, generating longer-term safety and benefit data for potential labeling

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Annexon, Inc. 8-K filings

Get the next ANNX 8-K as it lands

Follow ANNX for push alerts, or ask the research agent what this filing means.